DrugComb: an integrative cancer drug combination data portal

Drug combination therapy has the potential to enhance efficacy, reduce dose-dependent toxicity and prevent the emergence of drug resistance. However, discovery of synergistic and effective drug combinations has been a laborious and often serendipitous process. In recent years, identification of combination therapies has been accelerated due to the advances in high-throughput drug screening, but informatics approaches for systems-level data management and analysis are needed. To contribute toward this goal, we created an open-access data portal (https://drugcomb.fimm.fi) where the results of drug combination screening studies are accumulated, standardized and harmonized. Through the data portal, we provided the web server to analyze and visualize users’ own drug combination screening data. The users have an option to upload their data to DrugComb, as part of a crowdsourcing data curation effort. To initiate the data repository, we collected 437,932 drug combinations tested on a variety of cancer cell lines. We showed that linear regression approaches, when considering chemical fingerprints as predictors, have the potential to achieve high accuracy of predicting the sensitivity and synergy of drug combinations. All the data and informatics tools are freely available in DrugComb to enable a more efficient utilization of data resources for future drug combination discovery.

[1]  Albert-László Barabási,et al.  Network-based prediction of drug combinations , 2019, Nature Communications.

[2]  Florent Baty,et al.  Dose-Response Analysis Using R , 2015, PLoS ONE.

[3]  Yiling Lu,et al.  Characterization of Human Cancer Cell Lines by Reverse-phase Protein Arrays. , 2017, Cancer cell.

[4]  Krister Wennerberg,et al.  Methods for High-Throughput Drug Combination Screening and Synergy Scoring , 2016, bioRxiv.

[5]  George Papadatos,et al.  The ChEMBL database in 2017 , 2016, Nucleic Acids Res..

[6]  R. Tallarida,et al.  Quantitative methods for assessing drug synergism. , 2011, Genes & cancer.

[7]  Jing Tang,et al.  Informatics Approaches for Predicting, Understanding, and Testing Cancer Drug Combinations. , 2017, Methods in molecular biology.

[8]  Minoru Kanehisa,et al.  New approach for understanding genome variations in KEGG , 2018, Nucleic Acids Res..

[9]  Gerhard Dürnberger,et al.  A combinatorial screen of the CLOUD uncovers a synergy targeting the androgen receptor. , 2017, Nature chemical biology.

[10]  Sridhar Ramaswamy,et al.  Genomics of Drug Sensitivity in Cancer (GDSC): a resource for therapeutic biomarker discovery in cancer cells , 2012, Nucleic Acids Res..

[11]  Jean-Pierre Gillet,et al.  Toward a Better Understanding of the Complexity of Cancer Drug Resistance. , 2016, Annual review of pharmacology and toxicology.

[12]  Evan Bolton,et al.  PubChem 2019 update: improved access to chemical data , 2018, Nucleic Acids Res..

[13]  M. Berenbaum.  What is synergy? , 1989, Pharmacological reviews.

[14]  Robert Clarke,et al.  Enhancing reproducibility in cancer drug screening: how do we move forward? , 2014, Cancer research.

[15]  Brian Dumaine,et al.  Rethinking the war on cancer. , 2012, Fortune.

[16]  Gaelen T. Hess,et al.  Synergistic drug combinations for cancer identified in a CRISPR screen for pairwise genetic interactions , 2017, Nature Biotechnology.

[17]  Adam A. Margolin,et al.  The Cancer Cell Line Encyclopedia enables predictive modeling of anticancer drug sensitivity , 2012, Nature.

[18]  S. Gabriel,et al.  Discovery and saturation analysis of cancer genes across 21 tumor types , 2014, Nature.

[19]  Krister Wennerberg,et al.  Corrigendum to “Searching for drug synergy in complex dose–response landscapes using an interaction potency model” [Comput. Struct. Biotechnol. J. 13 (2015) 504–513] , 2017, Computational and structural biotechnology journal.

[20]  Yair Benita,et al.  An Unbiased Oncology Compound Screen to Identify Novel Combination Strategies , 2016, Molecular Cancer Therapeutics.

[21]  Krister Wennerberg,et al.  Quantitative scoring of differential drug sensitivity for individually optimized anticancer therapies , 2014, Scientific Reports.

[22]  Uciane K Scarlett,et al.  High-Throughput Testing of Novel-Novel Combination Therapies for Cancer: An Idea Whose Time Has Come. , 2016, Cancer discovery.

[23]  Tero Aittokallio,et al.  Network Pharmacology Strategies Toward Multi-Target Anticancer Therapies: From Computational Models to Experimental Design Principles , 2014, Current pharmaceutical design.

[24]  Elina Parri,et al.  Drug Target Commons: A Community Effort to Build a Consensus Knowledge Base for Drug-Target Interactions , 2017, Cell chemical biology.

[25]  Andreas Bender,et al.  Prediction of Antibiotic Interactions Using Descriptors Derived from Molecular Structure. , 2017, Journal of medicinal chemistry.

[26]  S. Loewe.  The problem of synergism and antagonism of combined drugs. , 1953, Arzneimittel-Forschung.

[27]  Amos Bairoch,et al.  The Cellosaurus, a Cell-Line Knowledge Resource. , 2018, Journal of biomolecular techniques : JBT.

[28]  S. Dixon,et al.  Systematic Quantification of Population Cell Death Kinetics in Mammalian Cells. , 2017, Cell systems.

[29]  Joshua A. Bittker,et al.  Harnessing Connectivity in a Large-Scale Small-Molecule Sensitivity Dataset. , 2015, Cancer discovery.

[30]  Tero Aittokallio,et al.  SynergyFinder: a web application for analyzing drug combination dose–response matrix data , 2017, Bioinform..

[31]  Larry Rubinstein,et al.  The National Cancer Institute ALMANAC: A Comprehensive Screening Resource for the Detection of Anticancer Drug Pairs with Enhanced Therapeutic Activity. , 2017, Cancer research.

[32]  Berenbaum Mc.  What is synergy? , 1989, Pharmacological reviews.

[33]  Jing Tang,et al.  What is synergy? The Saariselkä agreement revisited , 2015, Front. Pharmacol..

[34]  C. Cole,et al.  COSMIC (Catalogue of Somatic Mutations in Cancer) , 2014 .

[35]  Howard Lightfoot,et al.  Cell Model Passports—a hub for clinical, genetic and functional datasets of preclinical cancer models , 2018, Nucleic Acids Res..

[36]  Alan Ashworth,et al.  Synthetic lethality and cancer therapy: lessons learned from the development of PARP inhibitors. , 2015, Annual review of medicine.

[37]  Ping Zhang,et al.  DDI-CPI, a server that predicts drug–drug interactions through implementing the chemical–protein interactome , 2014, Nucleic Acids Res..

[38]  Erik Schultes,et al.  The FAIR Guiding Principles for scientific data management and stewardship , 2016, Scientific Data.

[39]  H. Wilkinson,et al.  A novel selective androgen receptor modulator (SARM) MK-4541 exerts anti-androgenic activity in the prostate cancer xenograft R–3327G and anabolic activity on skeletal muscle mass & function in castrated mice , 2016, The Journal of Steroid Biochemistry and Molecular Biology.

[40]  David M. Simcha,et al.  Tackling the widespread and critical impact of batch effects in high-throughput data , 2010, Nature Reviews Genetics.

[41]  David S. Wishart,et al.  DrugBank 5.0: a major update to the DrugBank database for 2018 , 2017, Nucleic Acids Res..

[42]  Damian Szklarczyk,et al.  STITCH 5: augmenting protein–chemical interaction networks with tissue and affinity data , 2015, Nucleic Acids Res..

[43]  Andreas Bender,et al.  DeepSynergy: predicting anti-cancer drug synergy with Deep Learning , 2017, Bioinform..

[44]  Michael T. McManus,et al.  Dual gene activation and knockout screen reveals directional dependencies in genetic networks , 2018, Nature Biotechnology.

[45]  Sridhar Ramaswamy,et al.  Patient-derived models of acquired resistance can identify effective drug combinations for cancer , 2014, Science.